LNX231 / Lunan Pharma - LARVOL DELTA

Discovery of LNX231, a multi-kinase inhibitor mainly target FLT3 with robust in vivo efficacy in FLT3 mutant AML models (AACR 2024) - "At the same dose, LNX231 was more potent than the FDA-approved drug Gilteritinib. In the MC38 tumor-bearing model, the efficacy of LNX231 was better than Sunitinib and Lenvatinib...LNX231 has low cardiotoxicity (IC50 of hERG is 25.84 µM) and 5-6 times safety window. In conclusion, we discovered LNX231 as a multi-kinase inhibitor for FLT3 mutated AML."

Preclinical • Acute Myelogenous Leukemia • Oncology • FLT3 • STAT5